| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| CDMO(元) | 11,776,037.89 | 5,556,835.54 | 10,524,584.08 | 4,489,203.56 |
| 抗病毒类药物中间体(元) | - | 7,788,134.18 | - | 8,960,177.03 |
| 抗过敏类药物中间体(元) | - | 22,645,955.50 | - | 31,993,869.76 |
| 抗血栓类药物中间体(元) | - | 35,822,540.92 | - | 39,505,581.26 |
| 胃溃疡类药物中间体(元) | - | 10,276,958.38 | - | 9,474,073.37 |
| 紫外线吸收剂(元) | 9,520,070.86 | 6,906,012.50 | 13,787,032.21 | 8,849,025.14 |
| 解热镇痛类(元) | 15,415,491.83 | - | 19,044,077.77 | - |
| 抗病毒类(元) | 9,143,178.43 | - | 25,501,734.52 | - |
| 抗过敏类(元) | 44,470,605.94 | - | 49,057,209.96 | - |
| 抗血栓类(元) | 70,131,492.08 | - | 79,057,652.85 | - |
| 抗氧化类(元) | 34,774,896.91 | - | 30,233,623.54 | - |
| 胃溃疡类(元) | 24,965,735.15 | - | 20,931,864.08 | - |
| 其他(元) | 6,055,661.23 | 5,309,272.23 | 10,553,950.13 | 8,259,461.41 |
| 营业成本(元) | ||||
| CDMO(元) | 6,883,674.58 | 1,220,188.71 | 2,753,197.06 | 1,171,195.20 |
| 抗病毒类药物中间体(元) | - | 6,022,905.59 | - | 7,107,201.88 |
| 抗过敏类药物中间体(元) | - | 13,253,133.59 | - | 19,152,624.08 |
| 抗血栓类药物中间体(元) | - | 19,930,820.26 | - | 22,131,957.05 |
| 胃溃疡类药物中间体(元) | - | 5,274,200.99 | - | 5,787,453.96 |
| 紫外线吸收剂(元) | 4,968,826.96 | 3,385,177.36 | 7,150,392.98 | 4,153,778.79 |
| 解热镇痛类(元) | 13,196,041.76 | - | 13,855,769.41 | - |
| 抗病毒类(元) | 5,967,472.26 | - | 20,251,207.30 | - |
| 抗过敏类(元) | 28,472,223.67 | - | 30,447,003.96 | - |
| 抗血栓类(元) | 40,218,659.29 | - | 47,747,597.37 | - |
| 抗氧化类(元) | 29,355,790.74 | - | 20,859,228.01 | - |
| 胃溃疡类(元) | 13,092,913.73 | - | 12,861,708.39 | - |
| 其他(元) | 2,777,808.16 | 4,225,121.78 | 6,411,939.06 | 4,272,089.14 |
| 毛利(元) | ||||
| CDMO(元) | 4,892,363.31 | 4,336,646.83 | 7,771,387.02 | 3,318,008.36 |
| 抗病毒类药物中间体(元) | - | 1,765,228.59 | - | 1,852,975.15 |
| 抗过敏类药物中间体(元) | - | 9,392,821.91 | - | 12,841,245.68 |
| 抗血栓类药物中间体(元) | - | 15,891,720.66 | - | 17,373,624.21 |
| 胃溃疡类药物中间体(元) | - | 5,002,757.39 | - | 3,686,619.41 |
| 紫外线吸收剂(元) | 4,551,243.90 | 3,520,835.14 | 6,636,639.23 | 4,695,246.35 |
| 解热镇痛类(元) | 2,219,450.07 | - | 5,188,308.36 | - |
| 抗病毒类(元) | 3,175,706.17 | - | 5,250,527.22 | - |
| 抗过敏类(元) | 15,998,382.27 | - | 18,610,206.00 | - |
| 抗血栓类(元) | 29,912,832.79 | - | 31,310,055.48 | - |
| 抗氧化类(元) | 5,419,106.17 | - | 9,374,395.53 | - |
| 胃溃疡类(元) | 11,872,821.42 | - | 8,070,155.69 | - |
| 其他(元) | 3,277,853.07 | 1,084,150.45 | 4,142,011.07 | 3,987,372.27 |
| 毛利率(%) | ||||
| CDMO(%) | 41.55 | 78.04 | 73.84 | 73.91 |
| 抗病毒类药物中间体(%) | - | 22.67 | - | 20.68 |
| 抗过敏类药物中间体(%) | - | 41.48 | - | 40.14 |
| 抗血栓类药物中间体(%) | - | 44.36 | - | 43.98 |
| 胃溃疡类药物中间体(%) | - | 48.68 | - | 38.91 |
| 紫外线吸收剂(%) | 47.81 | 50.98 | 48.14 | 53.06 |
| 解热镇痛类(%) | 14.40 | - | 27.24 | - |
| 抗病毒类(%) | 34.73 | - | 20.59 | - |
| 抗过敏类(%) | 35.98 | - | 37.94 | - |
| 抗血栓类(%) | 42.65 | - | 39.60 | - |
| 抗氧化类(%) | 15.58 | - | 31.01 | - |
| 胃溃疡类(%) | 47.56 | - | 38.55 | - |
| 其他(%) | 54.13 | 20.42 | 39.25 | 48.28 |
| 收入构成(%) | ||||
| CDMO(%) | 5.20 | 5.89 | 4.07 | 4.03 |
| 抗病毒类药物中间体(%) | - | 8.26 | - | 8.03 |
| 抗过敏类药物中间体(%) | - | 24.01 | - | 28.69 |
| 抗血栓类药物中间体(%) | - | 37.99 | - | 35.42 |
| 胃溃疡类药物中间体(%) | - | 10.90 | - | 8.49 |
| 紫外线吸收剂(%) | 4.21 | 7.32 | 5.33 | 7.93 |
| 解热镇痛类(%) | 6.81 | - | 7.36 | - |
| 抗病毒类(%) | 4.04 | - | 9.86 | - |
| 抗过敏类(%) | 19.66 | - | 18.96 | - |
| 抗血栓类(%) | 31.00 | - | 30.56 | - |
| 抗氧化类(%) | 15.37 | - | 11.69 | - |
| 胃溃疡类(%) | 11.03 | - | 8.09 | - |
| 其他(%) | 2.68 | 5.63 | 4.08 | 7.41 |
| 毛利构成(%) | ||||
| CDMO(%) | 6.02 | 10.58 | 8.07 | 6.95 |
| 抗病毒类药物中间体(%) | - | 4.31 | - | 3.88 |
| 抗过敏类药物中间体(%) | - | 22.91 | - | 26.89 |
| 抗血栓类药物中间体(%) | - | 38.77 | - | 36.38 |
| 胃溃疡类药物中间体(%) | - | 12.20 | - | 7.72 |
| 紫外线吸收剂(%) | 5.60 | 8.59 | 6.89 | 9.83 |
| 解热镇痛类(%) | 2.73 | - | 5.38 | - |
| 抗病毒类(%) | 3.91 | - | 5.45 | - |
| 抗过敏类(%) | 19.67 | - | 19.31 | - |
| 抗血栓类(%) | 36.78 | - | 32.49 | - |
| 抗氧化类(%) | 6.66 | - | 9.73 | - |
| 胃溃疡类(%) | 14.60 | - | 8.38 | - |
| 其他(%) | 4.03 | 2.64 | 4.30 | 8.35 |